Jungla Inc.

Jungla Inc. is an AI-driven biotechnology company enabling robust, scalable clinical guidance across genetic and genomic tests. (Acquired by Invitae in 2019.)

[Jungla Inc. @junglainc]

Genetic and genomic testing often provides patients with unclear results – @claraya explains how Jungla can help change that for labs, providers, and patients. https://t.co/vN4Wix9AXo #genomics #ai #precisionmedicine #beyondsequencing

[Jungla Inc. @junglainc]

If you’re in Seattle and excited about building a scalable, mechanistic platform for clinical genetics and genomics, come grab a beer. It’s on us: Big Time Brewery from 5:30-7:30pm (Today)!

[Jungla Inc. @junglainc]

You can read more at https://t.co/ZZrt6US2Sd and https://t.co/TFv8QI4cxi.

[Jungla Inc. @junglainc]

Nearly a year ago, we discovered in @Invitae a partner with a shared commitment towards perfecting diagnostics. Today, we are delighted to announce Jungla has signed an agreement for acquisition by Invitae to create the next generation of #clinical #genetics and #genomics.

[Jungla Inc. @junglainc]

Enhancing today’s largely observational #clinical #genetics infrastructure with a model-driven framework can bring #patients tests that are #quantitative, #auditable, #comprehensive, and increasingly #mechanistic. @MyBioTechniques interviews CEO @claraya: https://t.co/e13FOlavVK

[Jungla Inc. @junglainc]

In an interview with @GenomeWeb, Jungla CEO @claraya shares why three scientists from @Stanford came together to help make genomes more meaningful. Read more about the mission that @claraya, @acolavin, and @jasonareuter have undertaken: https://t.co/hyiF46b0TT

[Jungla Inc. @junglainc]

Jungla embraces transparency, utilizing blockchain to make the Molecular Evidence Platform auditable - learn more from a recent interview between cofounder @acolavin and @Tierion CEO @WayneVaughan.

https://t.co/ESYBSekLDH

[Jorge Conde @JorgeCondeBio]

Variants of Unknown Significance (VUS) remain a major challenge for interpreting genomic data. @junglainc is working to advance our ability to make sense of our DNA.

[Jay Rughani @JayRughani]

10+ new tests *each day* in US, yet vast majority of reported variants are still not understood: ~95 unknown per known disease-causing variant in most modern tests! We need tech for *computational* clinical genetics & genomics interpretation...and @junglainc can help!

[Antonio Neri @AntonioNeri_HPE]

Time is often the most valuable resource in the medical community. I'm excited to share that, together, @HPE and @junglainc are aiming to transform the world of medicine as we know it by reducing precious research time from years to weeks. https://t.co/PssX7Dbdw4 #HPEDiscover

[Vijay Pande @vijaypande]

ML combined with domain knowledge can push way beyond what ML can do alone. @junglainc combines ML with several other methods, including insights from biophysics, cellular engineering, and distributed systems, to make considerably more accurate predictions of genomic variants.

[SOSV SF & NY (Fka IndieBio) @indbio]

Learn how @junglainc has developed a cloud-based Molecular Evidence Platform (MEP) to help clinicians and patients understand the results of genetic and genomic tests... https://t.co/qoOfIl29ZH . #IndieBio @SOSVvc

[HPE @HPE]

HPE and biotech startup @junglainc announce challenge to enable real-time, personalized medical care for patients under Tech Impact 2030. Read more: https://t.co/SDFmHkwMka

[Jungla Inc. @junglainc]

We are delighted to be working with @HPE to bring state-of-the-art #biophysics and memory-driven computing into quantitative, mechanistic support for #precisionmedicine! With 250x speed-ups (48TB RAM) patients can receive the most advanced support on-demand. #ai #beyondsequencing

[HPE News @HPE_News]

Our genes make us who we are, but genetic variations are also a challenge to clinical care. With Memory-Driven Computing, @HPE and @junglainc hope to accelerate research aimed at identifying the correlation between our genes and disease. https://t.co/hVcaerRFlm #HPEDiscover

[JLABS @JLABS]

Enjoyed visit from @InaldeBS & @IAE_Austral to explore #Innovation-Special thanks to Carlos @junglainc, a #JLABSBay resident company. Shared his experience & work in AI-driven biotechnology to improve #genetic testing. Bonus-he delivered in our guests native language:) @prmansf

[Jungla Inc. @junglainc]

Enter an era of high-throughout, quantitative assays of biomolecular function. https://t.co/dMVdaFb5bt

[William J. Greenleaf @WJGreenleaf]

Our new preprint describing high-throughput protein assays on an Illumina sequencing chip is out; Congrats to Curtis Layton for great work! https://t.co/lbncwPgWnC

[Jungla Inc. @junglainc]

We are looking forward to the Gordon Research Seminar on Human Genetic Variation and Disease; if you’re excited about the impact of large-scale functional genomics, computational biophysics, and machine learning come meet our CEO @claraya at the Career Development Panel.

[Vikas Pejaver @vikaspejaver]

We have a great program this year. @anshulkundaje will be giving the keynote address, 8 exciting talks by junior trainees, and a panel on defining career paths. Panelists include Wei-Lun Alterovitz from @US_FDA , @claraya, @theFourier2k, @LuluP78 and Xin Wang from @23andMe

[Jungla Inc. @junglainc]

@biorxiv_genomic It is so exciting to see DMS data extending its impact beyond protein science and engineering into clinical genetics! Congrats @lea_starita!

[Jungla Inc. @junglainc]

We are proud to be a part of the growing healthcare innovation efforts that seek to make genomic information more actionable and reliable for all. https://t.co/Pdec5jHU6H

[Jorge Conde @JorgeCondeBio]

Enjoyed chatting w/@GabeOtte @freenome & @claraya @junglainc re: clinical genomics’ promise, peril & price tag @a16z https://t.co/ZqSWc8GuAo